M
Mary K. Crow
Researcher at Hospital for Special Surgery
Publications - 214
Citations - 19862
Mary K. Crow is an academic researcher from Hospital for Special Surgery. The author has contributed to research in topics: Systemic lupus erythematosus & Lupus erythematosus. The author has an hindex of 71, co-authored 203 publications receiving 17011 citations. Previous affiliations of Mary K. Crow include Rockefeller University & Cornell University.
Papers
More filters
Journal ArticleDOI
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
Mary J. Roman,Beth-Ann Shanker,Adrienne Davis,Michael D. Lockshin,Lisa R. Sammaritano,Ronit Simantov,Mary K. Crow,Joseph E. Schwartz,Stephen A. Paget,Richard B. Devereux,Jane E. Salmon +10 more
TL;DR: The clinical profile of patients with lupus and atherosclerosis suggests a role for disease-related factors in atherogenesis and underscores the need for trials of more focused and effective antiinflammatory therapy.
Journal ArticleDOI
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.
Jane Tian,Ana M. Avalos,Su-Yau Mao,Bo Chen,Kannaki Senthil,Herren Wu,Peggy Parroche,Stacey Drabic,Douglas T. Golenbock,Cherilyn M. Sirois,Jing Hua,Ling-Ling An,Laurent P. Audoly,Greg La Rosa,Angelika Bierhaus,Peter Naworth,Ann Marshak-Rothstein,Mary K. Crow,Katherine A. Fitzgerald,Eicke Latz,Peter A. Kiener,Anthony J. Coyle +21 more
TL;DR: HMGB1, a nuclear DNA-binding protein released from necrotic cells, was an essential component of DNA-containing immune complexes that stimulated cytokine production through a TLR9–MyD88 pathway involving the multivalent receptor RAGE.
Journal ArticleDOI
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer,Karen H. Costenbader,David I. Daikh,Ralph Brinks,Marta Mosca,Rosalind Ramsey-Goldman,Josef S Smolen,David Wofsy,Dimitrios T. Boumpas,Diane L. Kamen,David Jayne,Ricard Cervera,Nathalie Costedoat-Chalumeau,Betty Diamond,Dafna D. Gladman,Bevra H. Hahn,Falk Hiepe,Søren Jacobsen,Dinesh Khanna,Kirsten Lerstrøm,Elena Massarotti,Joseph M. McCune,Guillermo Ruiz-Irastorza,Jorge Sanchez-Guerrero,Matthias Schneider,Murray B. Urowitz,George Bertsias,Bimba F. Hoyer,Nicolai Leuchten,Chiara Tani,Sara K. Tedeschi,Zahi Touma,Gabriela Schmajuk,Branimir Anić,Florence Assan,Tak Mao Chan,Ann E. Clarke,Mary K. Crow,László Czirják,Andrea Doria,Winfried Graninger,Bernadett Halda-Kiss,Sarfaraz Hasni,Peter M. Izmirly,Michelle Jung,Gábor Kumánovics,Xavier Mariette,Ivan Padjen,José M. Pego-Reigosa,Juanita Romero-Diaz,Íñigo Rúa-Figueroa Fernández,Raphaèle Seror,Georg Stummvoll,Yoshiya Tanaka,Maria G Tektonidou,Carlos Vasconcelos,Edward M Vital,Daniel J. Wallace,Sule Yavuz,Pier Luigi Meroni,Marvin J. Fritzler,Ray Naden,Thomas Dörner,Sindhu R. Johnson +63 more
TL;DR: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism and the American College of Rheumatology (ACR).
Journal ArticleDOI
Systemic lupus erythematosus.
Arvind Kaul,Caroline Gordon,Mary K. Crow,Zahi Touma,Murray B. Urowitz,Ronald F van Vollenhoven,Guillermo Ruiz-Irastorza,Graham R. V. Hughes +7 more
TL;DR: The 10-year mortality has improved and toxic adverse effects of older medications such as cyclophosphamide and glucocorticoids have been partially offset by newer drugs such as mycophenolate mofetil and glucose-sparing regimes.
Journal ArticleDOI
Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
Kyriakos A. Kirou,Kyriakos A. Kirou,Christina Lee,Sandhya George,Kyriakos Louca,Margaret G. E. Peterson,Mary K. Crow +6 more
TL;DR: Activation of the IFNalpha pathway defines a subgroup of SLE patients whose condition is characterized by increased disease severity, including renal disease, increased disease activity, reflected in complement activation, and autoreactivity to RBP.